Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Bryan Johnson's new hair loss product, which includes peptides, is viewed skeptically by many, with concerns it may be a money grab rather than an effective treatment. Most users prefer proven treatments like finasteride and minoxidil, which are cheaper and have established results.

Finasteride prices vary widely across Europe, with some users opting to buy 5mg tablets and split them to save money. Many find 1mg tablets more expensive, and some suggest importing from countries like India for cheaper options.

A user shared progress pictures of a hair transplant from Padra Clinic in Toronto, claiming 8000 hairs were transplanted for $4000 CAD. The post faced skepticism, with users questioning the results and clinic's credibility, while the user mentioned using zinc, biotin, and hair laser therapy for aftercare.

Hair clinics prioritize making money over providing clear information. Effective treatments mentioned include oral finasteride and topical minoxidil.

FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.

The conversation is about a product called FLEAVA, found in a Facebook ad, and whether it is effective or just another scam. One user believes it is likely a scam and mentions that such products usually don't compete with Minoxidil.

Hair fibers effectively cover thin hair areas, boosting confidence and reducing stress about hair appearance. Users discuss combining hair fibers with other products like hair spray, dermmatch, and Boldify, noting challenges like blocking minoxidil absorption and the importance of color matching.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

The conversation discusses using Minoxidil with Tretinoin and Fexofenadine for hair loss. Some users doubt its effectiveness, noting Fexofenadine's unproven results for androgenetic alopecia.

A user in the UK is seeking recommendations for hair fibers. Nanogen is suggested as a good brand.

Alfatradiol helps reduce hair shedding and itching, and is effective for mild hair loss. Users combine it with treatments like fluridil, minoxidil, and sometimes consider finasteride.

Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.

The conversation discusses interest in participating in PP405 trials for hair loss treatment, with users expressing uncertainty about eligibility due to location. Participants are eager for updates and willing to pay for shipping if trials are limited to America.

A new FDA-cleared fractional laser treatment called FoLix is discussed as a potential alternative to hair transplants, but users express skepticism due to its high cost, pain, and lack of proven results. Some users prefer traditional methods like Minoxidil, finasteride, steroid shots, and microneedling for hair growth.

Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.

Folligenz liposomal minoxidil sulfate is being discussed for its effectiveness and cost, with users comparing it to regular minoxidil and tretinoin. One user found no difference with the 10% version and noted that a lower tretinoin percentage reduced side effects like skin peeling.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

2% fucoidan alleviated AGA symptoms, promoted hair growth, and increased hair density in mice. Fucoidan is considered safe for humans as a supplement and topical skincare product, with potential therapeutic effects against AGA.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

The conversation is about hair shedding experienced while using finasteride (fin) for hair loss treatment. Users discuss their experiences with finasteride, minoxidil (min), and other treatments, noting that shedding is often a sign that the treatment is working.

Foligain foam caused severe scalp irritation and flakiness, unlike Rogaine foam. The user plans to consult a dermatologist for treatment options.

Nizoral causes scalp and face itchiness and flakes. Piroctone olamine is suggested as an alternative.

The conversation is about identifying the vehicle used in the Breezula (clascoterone) trial for hair loss. No specific treatments were mentioned.

Hair regrowth treatments are effective in mice but not yet available for humans. The discussion humorously highlights frustration over this disparity and mentions a project to genetically modify elephants to resemble mammoths.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Breezula/Winlevi's potential use for hair loss is discussed, with concerns about its effectiveness compared to Breezula's higher concentration. Users express interest in a topical treatment with minimal side effects, noting that Breezula's efficacy may decline after six months.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Collagen peptides are recommended for hair and skin benefits, with users noting improvements in hair and skin health. However, evidence on their effectiveness for hair growth is inconclusive.